Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Long-term Activity Ratios (Summary)

Cytokinetics Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Net fixed asset turnover 0.10 0.13 1.24 1.18 1.85 1.92 0.86 0.96 0.40 1.56 2.52 4.18 7.08 3.33 4.31 5.93 8.58 12.09 10.93 9.83
Net fixed asset turnover (including operating lease, right-of-use asset) 0.05 0.06 0.61 0.58 0.95 1.00 0.44 0.48 0.16 0.48 0.57 3.43 7.08 3.33 4.31 5.93 8.58 12.09 10.93 9.83
Total asset turnover 0.01 0.01 0.11 0.09 0.14 0.20 0.08 0.08 0.03 0.10 0.10 0.10 0.11 0.08 0.09 0.09 0.17 0.18 0.17 0.15
Equity turnover 1.36 0.56 0.29 0.09 3.51 0.86 0.49 0.36 10.29 1.21

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Cytokinetics Inc. net fixed asset turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Cytokinetics Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Cytokinetics Inc. total asset turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Net Fixed Asset Turnover

Cytokinetics Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Revenues 378 867 4,613 1,957 2,515 88,968 1,148 55,600 5,437 2,843 6,548 6,722 41,688 3,593 3,825 5,212 6,055 7,137 8,464 9,377 10,641 6,215 5,268
Property and equipment, net 75,614 77,248 78,859 80,453 80,302 78,586 75,740 73,271 53,896 36,942 23,198 13,346 7,667 5,611 5,162 4,530 3,615 2,945 3,175 3,204 2,687 2,598 3,156
Long-term Activity Ratio
Net fixed asset turnover1 0.10 0.13 1.24 1.18 1.85 1.92 0.86 0.96 0.40 1.56 2.52 4.18 7.08 3.33 4.31 5.93 8.58 12.09 10.93 9.83
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 11.18 11.33 11.51 11.76 11.82 11.57 11.18 11.00 10.75 10.41 9.67 8.73 8.15 7.38 11.50 11.23
Amgen Inc. 4.61 4.58 4.56 4.57 4.73 4.77 4.75 4.69 4.89 4.92 4.93 4.96 4.94 4.78 4.68 4.51
Bristol-Myers Squibb Co. 6.93 7.11 7.30 7.38 7.74 7.90 7.77 7.67 7.75 7.66 7.43 7.22 6.86 6.03 5.07 4.18
Danaher Corp. 6.01 6.68 7.31 7.96 8.40 8.12 7.94 7.77 7.71 7.84 7.59 6.83 6.68 6.35 6.03 7.78
Eli Lilly & Co. 2.70 2.62 2.63 2.81 3.14 3.18 3.22 3.15 3.11 3.02 2.95 2.83 2.80 2.88 2.92 2.83
Gilead Sciences Inc. 4.88 4.91 4.88 4.93 5.01 5.13 5.18 5.27 5.40 5.27 5.06 4.90 4.74 4.70 4.90 4.91
Johnson & Johnson 4.65 4.37 4.58 4.79 5.29 5.21 5.07 4.95 4.95 4.79 4.59 4.40 4.53 4.57 4.75 4.65
Merck & Co. Inc. 2.63 2.62 2.66 2.77 2.89 2.85 2.73 2.53 2.57 2.61 2.55 2.67 2.80 2.99 3.15 3.11
Moderna Inc. 4.48 4.43 7.11 9.14 10.16 16.77 16.31 14.24 12.95 7.72 5.20 0.67 0.00 0.00 0.00 0.00
Pfizer Inc. 3.88 4.48 5.46 6.17 6.47 6.64 6.12 5.46 4.79 3.89 3.31 3.01 2.98 3.21 3.47 3.71
Regeneron Pharmaceuticals Inc. 3.27 3.23 3.19 3.23 3.70 3.91 4.64 4.62 3.99 3.69 2.82 2.64 2.63 2.64 2.71 2.72
Thermo Fisher Scientific Inc. 4.74 4.68 4.68 4.84 5.12 5.02 4.87 4.71 5.54 5.83 5.85 5.45 5.50 5.37 5.42 5.38

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Net fixed asset turnover = (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022) ÷ Property and equipment, net
= (378 + 867 + 4,613 + 1,957) ÷ 75,614 = 0.10

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Cytokinetics Inc. net fixed asset turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Cytokinetics Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Revenues 378 867 4,613 1,957 2,515 88,968 1,148 55,600 5,437 2,843 6,548 6,722 41,688 3,593 3,825 5,212 6,055 7,137 8,464 9,377 10,641 6,215 5,268
 
Property and equipment, net 75,614 77,248 78,859 80,453 80,302 78,586 75,740 73,271 53,896 36,942 23,198 13,346 7,667 5,611 5,162 4,530 3,615 2,945 3,175 3,204 2,687 2,598 3,156
Operating lease right-of-use assets 79,929 80,866 81,802 82,737 75,076 72,161 72,646 73,138 80,725 83,006 79,687 2,924
Property and equipment, net (including operating lease, right-of-use asset) 155,543 158,114 160,661 163,190 155,378 150,747 148,386 146,409 134,621 119,948 102,885 16,270 7,667 5,611 5,162 4,530 3,615 2,945 3,175 3,204 2,687 2,598 3,156
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 0.05 0.06 0.61 0.58 0.95 1.00 0.44 0.48 0.16 0.48 0.57 3.43 7.08 3.33 4.31 5.93 8.58 12.09 10.93 9.83
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
Moderna Inc. 3.22 4.19 6.72 8.62 9.62 15.35 14.85 12.78 11.40 6.83 4.19 0.52 0.00 0.00 0.00 0.00

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022) ÷ Property and equipment, net (including operating lease, right-of-use asset)
= (378 + 867 + 4,613 + 1,957) ÷ 155,543 = 0.05

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Cytokinetics Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Total Asset Turnover

Cytokinetics Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Revenues 378 867 4,613 1,957 2,515 88,968 1,148 55,600 5,437 2,843 6,548 6,722 41,688 3,593 3,825 5,212 6,055 7,137 8,464 9,377 10,641 6,215 5,268
Total assets 740,614 779,899 889,815 1,014,775 1,075,961 771,717 856,253 841,319 827,539 564,302 577,062 533,803 474,112 232,495 256,582 289,814 187,393 198,218 198,611 211,178 230,279 247,239 279,926
Long-term Activity Ratio
Total asset turnover1 0.01 0.01 0.11 0.09 0.14 0.20 0.08 0.08 0.03 0.10 0.10 0.10 0.11 0.08 0.09 0.09 0.17 0.18 0.17 0.15
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.40 0.41 0.42 0.42 0.41 0.40 0.40 0.38 0.37 0.36 0.33 0.30 0.27 0.24 0.37 0.37
Amgen Inc. 0.28 0.28 0.28 0.38 0.38 0.41 0.41 0.40 0.37 0.40 0.38 0.39 0.37 0.36 0.37 0.37
Bristol-Myers Squibb Co. 0.49 0.48 0.49 0.48 0.48 0.47 0.46 0.42 0.41 0.40 0.38 0.36 0.31 0.27 0.24 0.20
Danaher Corp. 0.29 0.33 0.35 0.37 0.39 0.38 0.36 0.35 0.34 0.34 0.33 0.29 0.28 0.27 0.26 0.29
Eli Lilly & Co. 0.55 0.54 0.52 0.58 0.62 0.62 0.62 0.58 0.58 0.56 0.54 0.53 0.53 0.55 0.56 0.57
Gilead Sciences Inc. 0.44 0.44 0.43 0.43 0.43 0.43 0.43 0.40 0.41 0.39 0.37 0.36 0.37 0.39 0.37 0.36
Johnson & Johnson 0.53 0.47 0.47 0.51 0.55 0.54 0.53 0.52 0.51 0.51 0.49 0.47 0.47 0.51 0.53 0.52
Merck & Co. Inc. 0.56 0.56 0.54 0.54 0.55 0.53 0.51 0.46 0.51 0.52 0.51 0.52 0.53 0.52 0.57 0.55
Moderna Inc. 0.45 0.46 0.59 0.71 0.79 0.85 0.79 0.72 0.52 0.38 0.15 0.03 0.00 0.00 0.00 0.00
Pfizer Inc. 0.32 0.36 0.48 0.51 0.51 0.52 0.50 0.45 0.39 0.33 0.29 0.27 0.24 0.25 0.29 0.31
Regeneron Pharmaceuticals Inc. 0.41 0.41 0.41 0.42 0.50 0.52 0.63 0.63 0.57 0.58 0.52 0.50 0.51 0.55 0.51 0.53
Thermo Fisher Scientific Inc. 0.45 0.46 0.46 0.46 0.49 0.47 0.44 0.41 0.53 0.57 0.54 0.47 0.44 0.43 0.44 0.44

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Total asset turnover = (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022) ÷ Total assets
= (378 + 867 + 4,613 + 1,957) ÷ 740,614 = 0.01

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Cytokinetics Inc. total asset turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Equity Turnover

Cytokinetics Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Revenues 378 867 4,613 1,957 2,515 88,968 1,148 55,600 5,437 2,843 6,548 6,722 41,688 3,593 3,825 5,212 6,055 7,137 8,464 9,377 10,641 6,215 5,268
Stockholders’ equity (deficit) (438,801) (333,115) (229,020) (107,900) (15,977) 111,414 116,261 243,863 249,020 16,489 67,846 113,383 149,605 (78,080) (45,711) (10,937) (19,869) (4,896) 3,372 25,934 52,069 75,170 99,599
Long-term Activity Ratio
Equity turnover1 1.36 0.56 0.29 0.09 3.51 0.86 0.49 0.36 10.29 1.21
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 4.56 4.35 4.27 3.36 3.62 3.91 3.48 3.65 4.07 4.27 3.66 3.50 2.66 2.46
Amgen Inc. 3.35 3.73 4.66 6.77 6.71 10.17 26.68 3.63 2.96 2.93 2.56 2.58 2.17 2.17 2.41 2.30
Bristol-Myers Squibb Co. 1.55 1.41 1.44 1.49 1.43 1.45 1.49 1.29 1.22 1.21 1.14 1.12 0.79 0.71 0.62 0.51
Danaher Corp. 0.49 0.54 0.58 0.63 0.67 0.66 0.65 0.65 0.65 0.62 0.61 0.56 0.54 0.52 0.58 0.59
Eli Lilly & Co. 2.86 2.67 2.47 2.68 2.90 3.40 3.14 3.15 3.58 4.15 3.69 4.35 4.81 5.61 7.50 8.56
Gilead Sciences Inc. 1.22 1.28 1.27 1.27 1.27 1.34 1.37 1.28 1.27 1.34 1.33 1.34 1.31 1.21 1.01 0.98
Johnson & Johnson 1.23 1.20 1.30 1.24 1.29 1.25 1.27 1.27 1.30 1.28 1.28 1.31 1.25 1.28 1.35 1.38
Merck & Co. Inc. 1.44 1.51 1.24 1.29 1.33 1.32 1.32 1.28 1.33 1.41 1.73 1.90 1.62 1.71 1.83 1.81
Moderna Inc. 0.65 0.60 0.76 0.96 1.14 1.23 1.28 1.25 1.08 0.91 0.50 0.08 0.00 0.00 0.00 0.00
Pfizer Inc. 0.71 0.79 0.92 1.05 1.08 1.16 1.12 1.05 0.91 0.79 0.68 0.66 0.66 0.70 0.75 0.82
Regeneron Pharmaceuticals Inc. 0.53 0.53 0.53 0.54 0.64 0.69 0.83 0.86 0.78 0.82 0.77 0.77 0.81 0.88 0.66 0.71
Thermo Fisher Scientific Inc. 0.96 0.99 1.04 1.02 1.01 1.01 1.00 0.96 1.01 1.04 1.02 0.93 0.90 0.88 0.90 0.86

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Equity turnover = (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022) ÷ Stockholders’ equity (deficit)
= (378 + 867 + 4,613 + 1,957) ÷ -438,801 =

2 Click competitor name to see calculations.